KAYAKU spirit是日本化药集团的应有形象(即企业愿景)。
作为实现KAYAKU spirit的企业活动有CSR(Corporate Social
Responsibility)经营。同时作为开展KAYAKU spirit的行动规范,制定了
集团行働指南、日本化药集团行为宪章•行为基准。
What's New
- 2023/12/15
- NIPPON KAYAKU ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH BIOCHEETAH FOR VECanDx TM IN JAPAN
- 2023/10/19
- Updated information of sustainability
- 2023/10/18
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication
- 2023/09/25
- Nippon Kayaku and Celltrion Announce Marketing Approval in Japan for Adalimumab Biosimilar Monoclonal Antibody.
- 2022/11/16
- Launch in Japan of Bevacizumab BS for I.V. Infusion 100mg・400mg “CTNK” ,an anti-VEGF humanized monoclonal antibody